Grant Number:	7R01CA125612-10 Interpret this number
Primary Investigator:	Rubin, Mark
Organization:	Universitat Bern
Project Title:	Towards Understanding Prostate Cancer Heterogeneity
Fiscal Year:	2017

DESCRIPTION (provided by applicant): Protein-altering point mutations are uncommon in prostate cancer. The overall and protein-altering mutation rate of primary prostate cancer is among the lowest reported, approximately an order of magnitude lower than other cancers. Consistent with this, recurrent protein-altering mutations are rare in prostate cancer. Mutations in AR, PTEN, and AKT1 are among the most common; these occur rarely in primary prostate cancer, with reported frequency around 1%. The SPOP gene (Speckle-type POZ Protein) encodes for the substrate-recognition component of a Cullin3- based E3-ubiquitin ligase. Mutations in SPOP in prostate cancer were recently reported in two systematic sequencing studies. We have identified the presence of recurrent mutations in SPOP in 6-13% of human prostate cancers in multiple independent patient cohorts (Barbieri et al., Nature Genetics 2012). Recurrent missense mutations were found exclusively in the structurally-defined substrate-binding cleft of SPOP, and structural analysis suggests that these mutations will inactivate SPOP function by disrupting SPOP-substrate interaction. Further, we found that loss of SPOP function in prostate cell lines resulted in increased invasion, and altered gene expression; evidence of this expression signature was identified in primary tumors harboring SPOP mutation. Importantly, all SPOP mutations occurred in tumors that were negative for ERG rearrangement and PTEN deletion; these tumors displayed characteristic somatic copy number aberrations. Taken together, these findings support a distinct molecular class of prostate cancer. The overall goal of this proposal is to define the role of SPOP mutations in prostate cancer and elucidate the biology of SPOP mutant prostate cancer as a distinct molecular subclass. We propose three specific Aims that together will examine the substrate specificity of SPOP mutant proteins, test the common SPOP mutations in an in vivo model of prostate cancer, identify cooperating and mutually exclusive genetic events, and examine the impact of SPOP mutation on prostate cancer patients. We will use a combination of biochemical, structural biology, in vivo and molecular biology approaches to study these events in prostate cancer models systems, while also employing large cohorts of primary and metastatic human prostate cancer samples to integrate genetic and epidemiologic analyses. Furthermore, we have assembled an outstanding team of co- investigators with complementary skills and resources to execute these proposed studies.




Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Authors: Cyrta J. , Prandi D. , Arora A. , Hovelson D.H. , Sboner A. , Rodriguez A. , Fedrizzi T. , Beltran H. , Robinson D.R. , Gopalan A. , et al. .
Source: The Journal Of Pathology, 2022-02-26 00:00:00.0; , .
EPub date: 2022-02-26 00:00:00.0.
PMID: 35220606
Related Citations

G3BP1 inhibits Cul3^SPOP to amplify AR signaling and promote prostate cancer.
Authors: Mukhopadhyay C. , Yang C. , Xu L. , Liu D. , Wang Y. , Huang D. , Deonarine L.D. , Cyrta J. , Davicioni E. , Sboner A. , et al. .
Source: Nature Communications, 2021-11-18 00:00:00.0; 12(1), p. 6662.
EPub date: 2021-11-18 00:00:00.0.
PMID: 34795264
Related Citations

Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.
Authors: Cyrta J. , Augspach A. , De Filippo M.R. , Prandi D. , Thienger P. , Benelli M. , Cooley V. , Bareja R. , Wilkes D. , Chae S.S. , et al. .
Source: Nature Communications, 2020-11-03 00:00:00.0; 11(1), p. 5549.
EPub date: 2020-11-03 00:00:00.0.
PMID: 33144576
Related Citations

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Authors: Beltran H. , Romanel A. , Conteduca V. , Casiraghi N. , Sigouros M. , Franceschini G.M. , Orlando F. , Fedrizzi T. , Ku S.Y. , Dann E. , et al. .
Source: The Journal Of Clinical Investigation, 2020-04-01 00:00:00.0; 130(4), p. 1653-1668.
PMID: 32091413
Related Citations

Ploidy- and Purity-Adjusted Allele-Specific DNA Analysis Using CLONETv2.
Authors: Prandi D. , Demichelis F. .
Source: Current Protocols In Bioinformatics, 2019 Sep; 67(1), p. e81.
PMID: 31524989
Related Citations

Genomic correlates of clinical outcome in advanced prostate cancer.
Authors: Abida W. , Cyrta J. , Heller G. , Prandi D. , Armenia J. , Coleman I. , Cieslik M. , Benelli M. , Robinson D. , Van Allen E.M. , et al. .
Source: Proceedings Of The National Academy Of Sciences Of The United States Of America, 2019-06-04 00:00:00.0; 116(23), p. 11428-11436.
EPub date: 2019-05-06 00:00:00.0.
PMID: 31061129
Related Citations

Tumor purity quantification by clonal DNA methylation signatures.
Authors: Benelli M. , Romagnoli D. , Demichelis F. .
Source: Bioinformatics (oxford, England), 2018-05-15 00:00:00.0; 34(10), p. 1642-1649.
PMID: 29325057
Related Citations

SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Authors: Shoag J. , Liu D. , Blattner M. , Sboner A. , Park K. , Deonarine L. , Robinson B.D. , Mosquera J.M. , Chen Y. , Rubin M.A. , et al. .
Source: The Journal Of Clinical Investigation, 2018-01-02 00:00:00.0; 128(1), p. 381-386.
EPub date: 2017-12-04 00:00:00.0.
PMID: 29202479
Related Citations

Molecular alterations in prostate cancer and association with MRI features.
Authors: Lee D. , Fontugne J. , Gumpeni N. , Park K. , MacDonald T.Y. , Robinson B.D. , Sboner A. , Rubin M.A. , Mosquera J.M. , Barbieri C.E. .
Source: Prostate Cancer And Prostatic Diseases, 2017 12; 20(4), p. 430-435.
EPub date: 2017-08-01 00:00:00.0.
PMID: 28762374
Related Citations

Spop Mutation Drives Prostate Tumorigenesis In vivo Through Coordinate Regulation Of Pi3k/mtor And Ar Signaling
Authors: Blattner M. , Liu D. , Robinson B.D. , Huang D. , Poliakov A. , Gao D. , Nataraj S. , Deonarine L.D. , Augello M.A. , Sailer V. , et al. .
Source: Cancer Cell, 2017-03-13 00:00:00.0; 31(3), p. 436-451.
PMID: 28292441
Related Citations

The Emergence Of Precision Urologic Oncology: A Collaborative Review On Biomarker-driven Therapeutics
Authors: Barbieri C.E. , Chinnaiyan A.M. , Lerner S.P. , Swanton C. , Rubin M.A. .
Source: European Urology, 2017 Feb; 71(2), p. 237-246.
PMID: 27567210
Related Citations

A Novel Brain Tumour Model In Zebrafish Reveals The Role Of Yap Activation In Mapk- And Pi3k-induced Malignant Growth
Authors: Mayrhofer M. , Gourain V. , Reischl M. , Affaticati P. , Jenett A. , Joly J.S. , Benelli M. , Demichelis F. , Poliani P.L. , Sieger D. , et al. .
Source: Disease Models & Mechanisms, 2017-01-01 00:00:00.0; 10(1), p. 15-28.
PMID: 27935819
Related Citations

SPOP mutation leads to genomic instability in prostate cancer.
Authors: Boysen G. , Barbieri C.E. , Prandi D. , Blattner M. , Chae S.S. , Dahija A. , Nataraj S. , Huang D. , Marotz C. , Xu L. , et al. .
Source: Elife, 2015-09-16 00:00:00.0; 4, .
EPub date: 2015-09-16 00:00:00.0.
PMID: 26374986
Related Citations

Genomic rearrangements in prostate cancer.
Authors: Barbieri C.E. , Rubin M.A. .
Source: Current Opinion In Urology, 2015 Jan; 25(1), p. 71-6.
PMID: 25393273
Related Citations

Defining Order And Timing Of Mutations During Cancer Progression: The To-dag Probabilistic Graphical Model
Authors: Lecca P. , Casiraghi N. , Demichelis F. .
Source: Frontiers In Genetics, 2015; 6, p. 309.
PMID: 26528329
Related Citations

Evidence for molecular differences in prostate cancer between African American and Caucasian men.
Authors: Khani F. , Mosquera J.M. , Park K. , Blattner M. , O'Reilly C. , MacDonald T.Y. , Chen Z. , Srivastava A. , Tewari A.K. , Barbieri C.E. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2014-09-15 00:00:00.0; 20(18), p. 4925-34.
EPub date: 2014-09-15 00:00:00.0.
PMID: 25056375
Related Citations

Unraveling the clonal hierarchy of somatic genomic aberrations.
Authors: Prandi D. , Baca S.C. , Romanel A. , Barbieri C.E. , Mosquera J.M. , Fontugne J. , Beltran H. , Sboner A. , Garraway L.A. , Rubin M.A. , et al. .
Source: Genome Biology, 2014-08-26 00:00:00.0; 15(8), p. 439.
EPub date: 2014-08-26 00:00:00.0.
PMID: 25160065
Related Citations

SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Authors: Blattner M. , Lee D.J. , O'Reilly C. , Park K. , MacDonald T.Y. , Khani F. , Turner K.R. , Chiu Y.L. , Wild P.J. , Dolgalev I. , et al. .
Source: Neoplasia (new York, N.y.), 2014 Jan; 16(1), p. 14-20.
PMID: 24563616
Related Citations

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.
Authors: Stoyanova T. , Cooper A.R. , Drake J.M. , Liu X. , Armstrong A.J. , Pienta K.J. , Zhang H. , Kohn D.B. , Huang J. , Witte O.N. , et al. .
Source: Proceedings Of The National Academy Of Sciences Of The United States Of America, 2013-12-10 00:00:00.0; 110(50), p. 20111-6.
EPub date: 2013-12-10 00:00:00.0.
PMID: 24282295
Related Citations

The mutational landscape of prostate cancer.
Authors: Barbieri C.E. , Bangma C.H. , Bjartell A. , Catto J.W. , Culig Z. , Grönberg H. , Luo J. , Visakorpi T. , Rubin M.A. .
Source: European Urology, 2013 Oct; 64(4), p. 567-76.
PMID: 23759327
Related Citations

Punctuated evolution of prostate cancer genomes.
Authors: Baca S.C. , Prandi D. , Lawrence M.S. , Mosquera J.M. , Romanel A. , Drier Y. , Park K. , Kitabayashi N. , MacDonald T.Y. , Ghandi M. , et al. .
Source: Cell, 2013-04-25 00:00:00.0; 153(3), p. 666-77.
PMID: 23622249
Related Citations

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Authors: Geng C. , He B. , Xu L. , Barbieri C.E. , Eedunuri V.K. , Chew S.A. , Zimmermann M. , Bond R. , Shou J. , Li C. , et al. .
Source: Proceedings Of The National Academy Of Sciences Of The United States Of America, 2013-04-23 00:00:00.0; 110(17), p. 6997-7002.
EPub date: 2013-04-23 00:00:00.0.
PMID: 23559371
Related Citations

Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.
Authors: Demichelis F. , Garraway L.A. , Rubin M.A. .
Source: Cancer Cell, 2013-02-11 00:00:00.0; 23(2), p. 133-5.
PMID: 23410968
Related Citations

Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer.
Authors: Elemento O. , Rubin M.A. , Rickman D.S. .
Source: Cell Cycle (georgetown, Tex.), 2012-09-15 00:00:00.0; 11(18), p. 3380-3.
EPub date: 2012-09-15 00:00:00.0.
PMID: 22918253
Related Citations

Oncogene-mediated alterations in chromatin conformation.
Authors: Rickman D.S. , Soong T.D. , Moss B. , Mosquera J.M. , Dlabal J. , Terry S. , MacDonald T.Y. , Tripodi J. , Bunting K. , Najfeld V. , et al. .
Source: Proceedings Of The National Academy Of Sciences Of The United States Of America, 2012-06-05 00:00:00.0; 109(23), p. 9083-8.
EPub date: 2012-06-05 00:00:00.0.
PMID: 22615383
Related Citations

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Authors: Barbieri C.E. , Baca S.C. , Lawrence M.S. , Demichelis F. , Blattner M. , Theurillat J.P. , White T.A. , Stojanov P. , Van Allen E. , Stransky N. , et al. .
Source: Nature Genetics, 2012-05-20 00:00:00.0; 44(6), p. 685-9.
EPub date: 2012-05-20 00:00:00.0.
PMID: 22610119
Related Citations

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Authors: Beltran H. , Rickman D.S. , Park K. , Chae S.S. , Sboner A. , MacDonald T.Y. , Wang Y. , Sheikh K.L. , Terry S. , Tagawa S.T. , et al. .
Source: Cancer Discovery, 2011 Nov; 1(6), p. 487-95.
PMID: 22389870
Related Citations

Characterization of KRAS rearrangements in metastatic prostate cancer.
Authors: Wang X.S. , Shankar S. , Dhanasekaran S.M. , Ateeq B. , Sasaki A.T. , Jing X. , Robinson D. , Cao Q. , Prensner J.R. , Yocum A.K. , et al. .
Source: Cancer Discovery, 2011 Jun; 1(1), p. 35-43.
PMID: 22140652
Related Citations

Testing mutual exclusivity of ETS rearranged prostate cancer.
Authors: Svensson M.A. , LaFargue C.J. , MacDonald T.Y. , Pflueger D. , Kitabayashi N. , Santa-Cruz A.M. , Garsha K.E. , Sathyanarayana U.G. , Riley J.P. , Yun C.S. , et al. .
Source: Laboratory Investigation; A Journal Of Technical Methods And Pathology, 2011 Mar; 91(3), p. 404-12.
PMID: 20975660
Related Citations

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
Authors: Pflueger D. , Terry S. , Sboner A. , Habegger L. , Esgueva R. , Lin P.C. , Svensson M.A. , Kitabayashi N. , Moss B.J. , MacDonald T.Y. , et al. .
Source: Genome Research, 2011 Jan; 21(1), p. 56-67.
PMID: 21036922
Related Citations

ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
Authors: Rickman D.S. , Chen Y.B. , Banerjee S. , Pan Y. , Yu J. , Vuong T. , Perner S. , Lafargue C.J. , Mertz K.D. , Setlur S.R. , et al. .
Source: Neoplasia (new York, N.y.), 2010 Dec; 12(12), p. 1031-40.
PMID: 21170267
Related Citations

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Authors: Palanisamy N. , Ateeq B. , Kalyana-Sundaram S. , Pflueger D. , Ramnarayanan K. , Shankar S. , Han B. , Cao Q. , Cao X. , Suleman K. , et al. .
Source: Nature Medicine, 2010 Jul; 16(7), p. 793-8.
PMID: 20526349
Related Citations

Antibody-based detection of ERG rearrangement-positive prostate cancer.
Authors: Park K. , Tomlins S.A. , Mudaliar K.M. , Chiu Y.L. , Esgueva R. , Mehra R. , Suleman K. , Varambally S. , Brenner J.C. , MacDonald T. , et al. .
Source: Neoplasia (new York, N.y.), 2010 Jul; 12(7), p. 590-8.
PMID: 20651988
Related Citations

ERG rearrangement metastasis patterns in locally advanced prostate cancer.
Authors: Perner S. , Svensson M.A. , Hossain R.R. , Day J.R. , Groskopf J. , Slaughter R.C. , Jarleborn A.R. , Hofer M.D. , Kuefer R. , Demichelis F. , et al. .
Source: Urology, 2010 Apr; 75(4), p. 762-7.
PMID: 20018353
Related Citations

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
Authors: Esgueva R. , Perner S. , J LaFargue C. , Scheble V. , Stephan C. , Lein M. , Fritzsche F.R. , Dietel M. , Kristiansen G. , Rubin M.A. .
Source: Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc, 2010 Apr; 23(4), p. 539-46.
PMID: 20118910
Related Citations

FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.
Authors: Sboner A. , Habegger L. , Pflueger D. , Terry S. , Chen D.Z. , Rozowsky J.S. , Tewari A.K. , Kitabayashi N. , Moss B.J. , Chee M.S. , et al. .
Source: Genome Biology, 2010; 11(10), p. R104.
PMID: 20964841
Related Citations

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Authors: Pflueger D. , Rickman D.S. , Sboner A. , Perner S. , LaFargue C.J. , Svensson M.A. , Moss B.J. , Kitabayashi N. , Pan Y. , de la Taille A. , et al. .
Source: Neoplasia (new York, N.y.), 2009 Aug; 11(8), p. 804-11.
PMID: 19649210
Related Citations

Distinct genomic aberrations associated with ERG rearranged prostate cancer.
Authors: Demichelis F. , Setlur S.R. , Beroukhim R. , Perner S. , Korbel J.O. , Lafargue C.J. , Pflueger D. , Pina C. , Hofer M.D. , Sboner A. , et al. .
Source: Genes, Chromosomes & Cancer, 2009 Apr; 48(4), p. 366-80.
PMID: 19156837
Related Citations

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Authors: Rickman D.S. , Pflueger D. , Moss B. , VanDoren V.E. , Chen C.X. , de la Taille A. , Kuefer R. , Tewari A.K. , Setlur S.R. , Demichelis F. , et al. .
Source: Cancer Research, 2009-04-01 00:00:00.0; 69(7), p. 2734-8.
EPub date: 2009-04-01 00:00:00.0.
PMID: 19293179
Related Citations

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
Authors: Narla G. , DiFeo A. , Fernandez Y. , Dhanasekaran S. , Huang F. , Sangodkar J. , Hod E. , Leake D. , Friedman S.L. , Hall S.J. , et al. .
Source: The Journal Of Clinical Investigation, 2008 Aug; 118(8), p. 2711-21.
PMID: 18596922
Related Citations